Managing Metastatic NSCLC: Strategies for Treatment Selection

This activity contains:

  • CME/CPE/CNE-Certified Live Grand Rounds and Webinars
  • Downloadable Slide Deck (a non-certified educational resource)
  • Pocket Reference Guide  (a non-certified educational resource)

Purpose
The goal of this activity is to educate clinicians about recent developments in the treatment of metastatic non–small cell lung cancer (NSCLC) and to provide them with the information necessary to make best use of the available therapies.

Course Overview
The treatment of NSCLC has changed significantly as a result of the identification of clinically relevant biomarkers and the development of targeted therapies. Although patient outcomes have improved as a result of treatment advances, metastatic disease is still an important challenge. Knowledge and practice gaps can be seen in several aspects of the treatment of metastatic NSCLC, such as how to integrate new therapies into practice, manage toxicities associated with new therapies, and make best use of a shared decision-making approach to treatment.

This Grand Rounds initiative is designed to close these knowledge gaps and provide clinicians with up-to-date information about therapies for NSCLC so that they can make informed choices regarding management and patient education. Topics covered in this activity include the indications, efficacy, and safety of recently approved therapies; how to integrate these therapies into practice; and how to apply a shared decision-making approach when working with patients who have metastatic NSCLC.

Target Audience

This activity is intended for community oncologists, nurses, pharmacists, and other healthcare professionals who manage NSCLC.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  1. Summarize the indications, efficacy, and safety profiles of recently approved therapies for NSCLC
  2. Devise treatment selection and drug sequencing strategies that incorporate newer therapies for patients with metastatic NSCLC
  3.  Implement management plans for the potential toxicities associated with therapies used for NSCLC
  4. Summarize the key components of patient education and shared decision making in the treatment of NSCLC  

Agenda

  • Activity Overview
  • The Foundation of Targeted Therapies for NSCLC
  • Treatment Strategies for Metastatic NSCLC
  • Case-Based Discussion of Treatment Selection and Shared Decision Making
Course summary
Available credit: 
  • 1.00 ACPE
  • 1.00 ANCC
  • 1.00 AMA PRA Category 1 Credit™
Course opens: 
07/12/2016
Course expires: 
01/05/2018
Cost:
$0.00
Rating: 
0

Chairperson

David S. Ettinger, MD, FACP, FCCP
Alex Grass Professor of Oncology 
Professor of Medicine
Professor of Otolaryngology-Head and Neck Surgery
Professor of Gynecology and Obstetrics
Professor of Radiation Oncology and Molecular Radiation Sciences
The Johns Hopkins University School of Medicine 
Baltimore, Maryland

Faculty Speakers

 

Jeffrey Crawford, MD
George Barth Geller Professor for Research in Cancer
Duke University Medical Center
Co-Director of the Solid Tumor Therapeutics Program
Duke Cancer Institute
Durham, North Carolina

Barbara J. Gitlitz, MD
Associate Professor of Clinical Medicine
Keck School of Medicine
University of Southern California
Los Angeles, California

Fred R. Hirsch, MD, PhD
Endowed Chair in Lung Cancer Research
University of Colorado
Professor of Medicine and Pathology
University of Colorado Cancer Center
Denver

Leora Horn, MD, MSc, FRCPC
Clinical Director Thoracic Oncology Program
Vanderbilt Ingram Cancer Center
Associate Professor, Department of Medicine
Assistant Vice Chancellor for Faculty Development
Vanderbilt University
Nashville, Tennessee 

Benjamin Levy, MD
Director of Thoracic Medical Oncology
Mount Sinai Health Systems
Assistant Professor of Medicine
Icahn School of Medicine
New York, New York

Roman Perez-Soler, MD
Professor of Medicine
Chairman, Department of Oncology
Montefiore Medical Center
Director, Division of Medical Oncology
Albert Einstein College of Medicine
Deputy Director
Albert Einstein Cancer Center
Bronx, New York

David Spigel, MD
Chief Scientific Officer
Director, Lung Cancer Research Program
Principal Investigator
Sarah Cannon Research Institute
Medical Oncologist, Tennessee Oncology
Nashville, Tennessee


Continuing Medical Education
Accreditation Statement
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hours of continuing pharmacy education credit. UAN 0592-0000-16-016-L01-P.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.

Iowa Board of Nursing
AXIS is Iowa Board of Nursing Approved Provider Number 371, for 1.0 contact hour. 

Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. 

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or PresenterReported Financial Relationship
David S. Ettinger, MD, FACP, FCCPResearch grant: Golden Biotech Corp; Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Ariad Pharmaceuticals, Inc; Boehringer Ingelheim; Bristol-Myers Squibb Co; Eli Lilly and Co; EMD Serono, Inc; Genentech, Inc; Helsinn Therapeutics (US) Inc.
Jeffrey Crawford, MDData and safety monitoring board member: Celgene Corp; G1 Therapeutics; Janssen Pharmaceuticals, Inc; Merrimack Pharmaceuticals; Roche; Institutional principal investigator: Amgen, Inc; AstraZeneca Pharmaceuticals LP; Bayer Pharmaceuticals Corp; Clovis Oncology; GTx; MedImmune; Scientific advisor: Merck & Co, Inc; Novartis Pharmaceuticals Corp; Pfizer, Inc.
Barbara J. Gitlitz, MDAdvisor: Ariad Pharmaceuticals, Inc; Celgene Corp; Clovis Oncology; Serve(d) as a speaker or a member of a speakers bureau for: Eli Lilly and Co; Genentech, Inc.
Fred R. Hirsch, MD, PhDConsultant/Advisory boards: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Co; Eli Lilly and Co; Genentech, Inc; Merck & Co., Inc; Ventana; Research grant through University of Colorado Lab: Amgen, Inc; Bayer Pharmaceuticals Corp; Eli Lilly and Co; Genentech, Inc.
Leora Horn, MD, MSc, FRCPCServe(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Bayer Pharmaceuticals Corp; Boehringer Ingelheim; Bristol-Myers Squibb Co; Eli Lilly and Co; Genentech, Inc; Merck & Co, Inc; Xcovery; Serve(d) as a speaker or a member of a speakers bureau for: Biodesix, Inc.
Benjamin Levy, MDReceived income in any amount from: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim; Celgene Corp; Eli Lilly and Co; Genentech, Inc; Merck & Co, Inc; Pfizer, Inc; Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim; Celgene Corp; Eli Lilly and Co; Genentech, Inc; Merck & Co, Inc; Pfizer, Inc; Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc.
Roman Perez-Soler, MDNo real or apparent conflicts of interest to report.
David Spigel, MDNo real or apparent conflicts of interest to report.


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda-Gracie-King, MS, Ronald Viggiani, MD, Isabelle Vacher, Sarah Williams, PhD, Jocelyn Timko, and Marilyn Haas, PhD, RN, CNS, ANP-BC state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.      


This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

There is no fee for this educational activity.

This activity is provided by

AXIS 1483

Available Credit

  • 1.00 ACPE
  • 1.00 ANCC
  • 1.00 AMA PRA Category 1 Credit™

Accreditation Period

Course opens: 
07/12/2016
Course expires: 
01/05/2018

Price

Cost:
$0.00
Please login or register to take this course.